Gen XY Updates from GlobeNewswire

Online Casino Bonus Leader Lucky Creek Casino Recognized by CasinoTop10.net for 2025 Promotions Excellence
2025-11-09T00:29:39Z
CasinoTop10.net Names Lucky Creek Casino a 2025 Leader in Online Bonus Rewards

NFL Betting Sites: Bovada NFL Betting Recognized in CasinoTop10’s 2025 Sportsbook Rankings
2025-11-09T00:27:41Z
Bovada earns recognition in CasinoTop10’s 2025 Sportsbook Rankings for its NFL betting coverage, competitive odds, player promotions, and secure mobile experience trusted by U.S. bettors.

NFL Betting Promos: BetUS' New Customer Bonus for NFL Betting
2025-11-09T00:06:46Z
BetUS Launches 2025 NFL Betting Bonus for New Customers Ahead of the Season Kickoff.

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
2025-11-08T22:13:00Z
CAMBRIDGE, Mass., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented positive clinical...

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
2025-11-08T19:30:00Z
Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
2025-11-08T16:45:00Z
Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
2025-11-08T16:30:00Z
Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
2025-11-08T16:25:00Z
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research

Judo Bio’s Megalin-STRIKERs Achieve First Demonstration of Functional Pharmacodynamic Effects from Kidney Selective Gene Silencing in Non-Human Primates
2025-11-08T16:00:00Z
Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels lasting for at least 2 months

Most Trusted Crypto Casinos USA: Jackbit Leads 2025 Crypto Gaming With Instant Withdrawals & No KYC Access
2025-11-08T16:00:00Z
Jackbit, a crypto casino founded in 2022, has quickly built a reputation as the most trusted gambling platform in the US, according to 30+ review platforms

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
2025-11-08T16:00:00Z
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies...

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
2025-11-08T15:46:31Z
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
2025-11-08T15:41:00Z
- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:

Dancetime Launches Guide to Top 8 Outdoor Party Hire Essentials Amid Surge in Sydney Events
2025-11-08T15:00:00Z
Effortless Outdoor Celebrations: Dancetime Reveals the 8 Must-Have Party Hire Items

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
2025-11-08T14:56:00Z
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025-

MemoMaster Unveiled: How This Memo Master Cutting-Edge Brain Support Supplement Is Redefining Focus and Memory Health for the Digital Era
2025-11-08T12:53:23Z
Boost memory, focus & mental clarity with MemoMaster – a clinically inspired brain supplement for sharper thinking, sustained energy & long-term brain health.

Novo Nordisk will not increase its proposal to acquire Metsera, Inc. 
2025-11-08T08:19:11Z
Bagsværd, Denmark, 8 November 2025 – Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera.

Fangzhou Awarded “Golden Bull Award” for Leadership in AI-Powered Chronic Disease Management
2025-11-08T06:07:33Z
XIAMEN, China, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, was recognized with the “Social Responsibility...

Smile Spa Camarillo Officially Opens its Doors, Offering State-of-the-Art Dental Care in Ventura County
2025-11-08T01:31:00Z
Camarillo, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Smile Spa Camarillo, a modern dental office led by Dr. Joelle Abed Elahad and Dr. Shawn Nguyen, is proud to announce that...

Aeroméxico Announces Webcast of Third Quarter 2025 Financial Results
2025-11-07T23:42:21Z
MEXICO CITY, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Grupo Aeroméxico S.A.B. de C.V. (NYSE & BMV: AERO) (“Aeroméxico”) will hold a live conference call and webcast on Wednesday, November 12,...

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
2025-11-07T23:27:20Z
BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological...

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
2025-11-07T23:10:00Z
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
2025-11-07T23:00:00Z
PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation...

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
2025-11-07T22:10:00Z
COPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with...

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
2025-11-07T21:45:00Z
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-07T21:30:00Z
CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-11-07T21:30:00Z
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of...

Cannabix Technologies announces Non-Brokered LIFE Private Placement
2025-11-07T21:30:00Z
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES ORFOR DISSEMINATION IN THE UNITED STATES

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-07T21:30:00Z
Lasme-cel in r/r B-ALL (BALLI-01)

Spyre Therapeutics Announces Grants of Inducement Awards
2025-11-07T21:05:00Z
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the...

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-07T21:05:00Z
BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera...

Nanox to Report Third Quarter 2025 Financial Results on November 20, 2025
2025-11-07T21:05:00Z
PETACH TIKVA, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report...

Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights
2025-11-07T21:05:00Z
-- Zola® year-to-date revenues increase 26% year over year ---- Arcadia gross profit margins exceed 30% for 11th straight quarter ---- Arcadia cash balance declines by only $257K to $1.1M...

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-07T21:05:00Z
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway...

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
2025-11-07T21:05:00Z
JENA, Germany, Nov. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it expects to report...

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
2025-11-07T21:05:00Z
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant...

BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2025-11-07T21:05:00Z
MENLO PARK, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today...

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-07T21:01:00Z
NAARDEN, The Netherlands and MIAMI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin...

Exicure, Inc. Reports Third Quarter 2025 Financial Results
2025-11-07T21:00:00Z
REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-07T21:00:00Z
WESTLAKE VILLAGE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an...

Maximus Announces First-Ever Topical Oxytocin Cream for Mood Enhancement and Sleep Support
2025-11-07T20:56:53Z
Breakthrough Transdermal Technology Overcomes Decades-Old Challenge in Oxytocin Delivery

All Smiles Dental Studio Launches Full Dental Implant Services and In-House Membership Plan to Support the Encinitas Community
2025-11-07T19:40:44Z
Encinitas, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- All Smiles Dental Studio, a leading dental care provider serving North County San Diego, is pleased to announce the expansion of its...

Protext Mobility, Inc. (OTC: TXTM) Announces Launch Phase of Its Next-Generation Investor Relations Suite and Corporate Website Modernization — Ushering in a New Era of Transparency, Innovation, and Shareholder Confidence
2025-11-07T19:13:39Z
NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM), an emerging leader in botanical-based biotechnology and NANOTECHNOLOGY, today announced the launch and completion phase of its...

PetVivo Sets Fiscal Second Quarter 2026 Conference Call for Friday, November 14, 2025 at 5:00 p.m. ET
2025-11-07T18:18:54Z
MINNEAPOLIS, MN, US, Nov. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and its wholly-owned subsidiary Petvivo Animal Health, Inc., a leading biomedical company delivering innovative...

Table Trac Announces Quarterly Dividend
2025-11-07T17:56:00Z
MINNETONKA, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- On November 7, 2025, The Board of Directors of Table Trac Inc. (the “Company”) (OTCQX: TBTC) approved a cash dividend on the...

Neurocept Unveiled: Exploring the Science Behind This Neurocept Brain Support Supplement Transforms Cognitive Health and Memory Enhancement
2025-11-07T17:41:22Z
Experience sharper focus, stronger memory, and peak cognitive performance with Neurocept—an advanced brain support supplement backed by science.

Fagron’s share buy-back program: Weekly update
2025-11-07T17:39:30Z
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 November 2025 – 6PM CET

IBA – Regulated information
2025-11-07T17:00:00Z
November 7th, 2025

Ipsen - October 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
2025-11-07T17:00:00Z
Monthly information relative to the total number of voting rights and shares composing the share capital

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
2025-11-07T17:00:00Z
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines